Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS

Core Viewpoint - Boston Scientific (BSX) is expected to report quarterly earnings of $0.72 per share, reflecting a 16.1% increase year-over-year, with revenues projected at $4.89 billion, an 18.7% increase compared to the previous year [1]. Financial Performance Estimates - Analysts anticipate 'Net Sales- MedSurg- Worldwide' to reach $1.68 billion, indicating a 13.1% increase from the prior-year quarter [4]. - The estimated 'Net Sales- Cardiovascular- Worldwide' is projected at $3.21 billion, representing a 21.7% increase year-over-year [4]. - 'Net Sales- Cardiovascular- Cardiology- Worldwide' is expected to be $2.52 billion, showing a 23.3% increase from the previous year [5]. - 'Net Sales- Cardiovascular- Peripheral Interventions- Worldwide' is forecasted at $689.56 million, indicating a 16.9% year-over-year change [5]. - 'Geographic Revenue- U.S.' is likely to reach $3.06 billion, reflecting a 24.1% increase year-over-year [6]. - 'Net Sales- Cardiovascular- Peripheral Interventions- International' is projected at $309.92 million, indicating a 10.3% increase from the prior year [6]. - 'Net Sales- MedSurg- Neuromodulation- United States' is expected to be $220.82 million, showing a 3.2% increase year-over-year [7]. - 'Net Sales- MedSurg- Neuromodulation- International' is forecasted at $70.31 million, reflecting a 3.4% increase [7]. - 'Net Sales- MedSurg- Endoscopy- United States' is projected at $445.09 million, indicating a 7.3% increase year-over-year [8]. - 'Net Sales- MedSurg- Endoscopy- International' is expected to reach $273.79 million, reflecting a 4.9% increase [8]. - 'Net Sales- MedSurg- Urology- United States' is forecasted at $492.40 million, indicating a significant 35.7% increase year-over-year [8]. - 'Net Sales- MedSurg- Urology- International' is projected at $177.83 million, reflecting a 9.8% increase [9]. Market Performance - Over the past month, shares of Boston Scientific have returned +3.2%, compared to the Zacks S&P 500 composite's +5.4% change [9]. - Currently, BSX holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [9].